Whalesbook
Regulatory Shift: From Voluntary to Rigorous
The government's recent report to the Convention on Biological Diversity marks a significant change in enforcing the Access and Benefit Sharing (ABS) framework. The report documents 12,830 approvals over eight years, indicating that companies' use of India's indigenous genetic resources is no longer a minor operational cost. It's now a structured financial commitment affecting research and development for businesses using natural ingredients. The collection of ₹216.31 crore shows the National Biodiversity Authority is actively collecting these fees, moving beyond guidelines to real revenue.
Rising Corporate Expenses and Oversight
Companies like Sun Pharmaceutical Industries and Indian Oil Corporation will see these ABS payments as just the start of their commitments to conservation. These payments are directly linked to using specific local biological resources, creating a variable cost based on regional approvals. While the current amounts may seem small compared to large companies' revenues, they add up as a regular compliance cost. With the government improving digital tracking, there's a growing potential for audits and closer monitoring of resource use, requiring businesses to strengthen their internal accounting for biodiversity compliance.
Risks and Future Challenges
The current system has significant challenges for businesses using biological resources. The ministry itself notes that valuation methods need improvement, suggesting future ABS payments could become less predictable. If the government adopts market-based valuations, costs could rise sharply. Differences in how state-level biodiversity boards interpret sharing rules could also cause project delays. Companies might also face pressure to fund local development projects as part of community benefits, turning compliance payments into open-ended social obligations.
Market Integration and Standardization
The government aims to streamline the ABS Clearing-House, which already handles 60% of global compliance certificates. This points to a future of total standardization. Investors should expect more digital processes, greater transparency, and stricter enforcement. As India leads in biodiversity governance, the cost of using natural biological inputs will become a key governance consideration, not just an administrative task. Companies that formally manage these contributions will likely face fewer regulatory issues than those handling it case by case.